v3.26.1
Basic and diluted net loss per share (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Denominator for basic and diluted loss per share              
Weighted-average ordinary shares outstanding, Basic 100 100          
Weighted-average ordinary shares outstanding, diluted 100 100          
Basic loss per share $ (5.90) $ (100.00)          
Diluted loss per share $ (5.90) $ (100.00)          
Exascale Labs Inc. [Member]              
Net loss attributable to ordinary shareholders   $ (2,632,431) $ (1,537,059) $ (7,916,977) $ (6,178,537) $ (7,659,667) $ (4,956,347)
Denominator for basic and diluted loss per share              
Weighted-average ordinary shares outstanding, Basic   1,500 [1] 1,500 [1] 1,500 [1] 1,500 [1] 1,500 [2] 1,500 [2]
Weighted-average ordinary shares outstanding, diluted   1,500 [1] 1,500 [1] 1,500 [1] 1,500 [1] 1,500 [2] 1,500 [2]
Basic loss per share   $ (1,754.95) [3] $ (1,024.70) [3] $ (5,277.98) [3] $ (4,119.02) [3] $ (5,106.44) $ (3,304.23)
Diluted loss per share   $ (1,754.95) [3] $ (1,024.70) [3] $ (5,277.98) [3] $ (4,119.02) [3] $ (5,106.44) $ (3,304.23)
[1] In January 2026, the Company adopted an Amended and Restated Certificate of Incorporation, which established a dual-class ordinary share structure. Under this new structure, the Company’s equity is divided into 303 Class A ordinary shares and 1,197 Class B ordinary shares, which are entitled to one (1) vote and twenty (20) votes per share, respectively. Despite the differential in voting power, Class A and Class B ordinary shares rank pari passu in all other respects, sharing ratably in dividends and any distributions upon liquidation.
[2] The Company’s share-based compensation awards are expected to be settled through transfers of existing ordinary shares held by the controlling shareholder, rather than through the issuance of new shares by the Company. The underlying ordinary shares are included in issued and outstanding shares as of the balance sheet date; accordingly, such settlement is not expected to increase the Company’s total issued and outstanding shares. During the years ended June 30, 2024 and 2025, diluted net loss per share is calculated in the same manner as basic net loss per share.
[3] During the three and nine months ended March 31, 2025 and 2026, diluted net loss per share is calculated in the same manner as basic net loss per share, as the Company was in a net loss position and all potential ordinary shares were anti-dilutive.